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We report a patient who presented a non-ST segment elevation myocardial infarction
in the context of severe normocytic hypochromic anemia related to gastrointestinal
bleeding, 3 months after switching anticoagulant from the vitamin K antagonist
acenocoumarol to the direct oral anticoagulant rivaroxaban. High levels of both anti-
Xa activity and rivaroxaban plasma concentrations were measured despite rivaroxaban
withdrawal, suggesting reduced elimination/drug clearance. Estimated half-life was
2–3 times longer than usually reported. The patient is a homozygous carrier of ABCB1
variant alleles, which could have participated to reduced elimination of rivaroxaban.
Furthermore, CYP3A4/5 phenotyping showed moderately reduced enzyme activity.
Drug-drug interaction with simvastatin may have contributed to decreased rivaroxaban
elimination. Although in the present case moderate acute renal failure probably played a
role, more clinical data are required to elucidate the impact of ABCB1 polymorphism on
rivaroxaban pharmacokinetics and bleeding complications.
Keywords: direct oral anticoagulants, adverse drug reaction, genetic polymorphism, ABCB1, CYP3A4/5, drug-
drug interaction
INTRODUCTION
Rivaroxaban is a direct Factor Xa inhibitor which has been approved for specific thromboembolic
disorders such as the prevention of stroke and systemic embolism in adults with non-valvular
atrial fibrillation (Mueck et al., 2014). Rivaroxaban is both excreted as unchanged drug in urine
and through metabolic transformation. P-glycoprotein (P-gp) and breast cancer resistance protein
(BCRP), as well as cytochrome P450 (CYP) 3A4/5 have been shown to play major roles in
rivaroxaban transport and metabolism, respectively (Mueck et al., 2014). The administration of
strong inhibitors of CYP3A4/5 and P-gp/BCRP such as ritonavir and ketoconazole has been shown
to increase rivaroxaban exposure and cases of severe bleeding have been reported (Mueck et al.,
2013). However, to the best of our knowledge, no human data has described the impact of genetic
polymorphism of ABCB1 and/or ABCG2 on the pharmacokinetics and safety of rivaroxaban.
ABCB1 and ABCG2 genes encode for P-gp and BCRP eﬄux transporter, respectively, (Hodges
et al., 2011; Giacomini et al., 2013). We report here a rivaroxaban-treated patient who presented
with severe anemia related to gastrointestinal bleeding and in whom ABCB1 genetic polymorphism
and drug-drug interaction (DDI) may have been contributing factors. The patient gave his written
informed consent for publication of this report.
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CASE PRESENTATION
Our patient is a 79-year-old male suffering from systolic
cardiac failure (ischemic, rhythmic, and valvular) and type
2 diabetes mellitus. The patient had received rivaroxaban
20 mg q.d. since September 2015 for cardioembolic strokes
and atrial fibrillation. Before the introduction of rivaroxaban,
he had been treated with acenocoumarol for years. The
patient was hospitalized on December 15th 2015 for non-
ST segment elevation myocardial infarction (NSTEMI). At
hospital admission, laboratory testing showed severe normocytic
hypochromic anemia with a hemoglobin level at 70 g/l (normal
range: 140–180 g/l), without hemodynamic instability. The
patient received erythrocyte transfusions, which raised the
hemoglobin to 105–110 g/l. Acute renal failure was also
diagnosed with a CLCR value at 39 ml/min using the Cockcroft–
Gault equation at admission. Renal function improved at
57 ml/min 4 days later. Due to the presence of fecal occult blood
on two occasions, iron loss from gastrointestinal bleeding was
suspected. The colonoscopy did not show any evidence of colon
injury; however, inadequate bowel preparation was highlighted
by the examinator. Gastroscopy could not be performed because
the patient’s comorbidities exposed him to high risks in case
of general anesthesia. Rivaroxaban was stopped at admission;
enoxaparin was introduced 4 days later and then switched to
acenocoumarol.
The other patient medications before hospitalization were:
insulin, simvastatin 40 mg q.d., levothyroxine 75 µg q.d.,
extended-release metoprolol 25 mg q.d., and enalapril 10 mg q.d.
INVESTIGATIONS
Clinical investigations were performed to assess for causes of
potential increased rivaroxaban effects at therapeutic doses.
They included anti-Xa activity measurement, rivaroxaban plasma
concentrations measurement, as well as ABCB1 genotyping, and
CYP3A4/5 phenotyping.
Anti-Xa Activity
Anti-Xa activity was measured with a chromogenic assay using
the DiXal R© kit (Hyphen Biomed, Neuville-Sur-Oise, France)
and a BCS XP instrument (Siemens, Marburg, Germany).
This method has a limit of detection of 10 ng/ml. No
information is given by the manufacturer regarding the limit
of quantification (LOQ). However, previous studies have shown
a LOQ of 20–30 ng/ml (Douxfils et al., 2013). The accuracy
and precision calculated from the quality controls (QCs) were
107.0 and 8.8%, respectively, (Asmis et al., 2012). An excellent
correlation between this method and liquid chromatography-
tandem mass spectrometry (LC-MS/MS) has been shown
(Spearman correlation coefficient of 0.96) (Douxfils et al.,
2013).
Rivaroxaban Plasma Concentrations
Rivaroxaban determination was performed using a fully validated
LC-MS/MS method according to guidelines of the US Food
and Drug Administration and the International Conference on
Harmonization. The method was accurate and precise across the
dynamic range of 0.5–1000 ng/ml. The LOQ was 0.5 ng/ml. The
mean precision and accuracy, calculated from the QCs, were 10.2
and 112%, respectively.
A plasma sample of 40 µl was processed by protein
precipitation extraction using acetonitrile (200 µL). Separation
was performed on a C18 column (50 mm × 2.1 mm ID; 2.6 µm
particle size) and under gradient conditions using formic acid
10 mM in water and formic acid 10 mM in acetonitrile. Detection
was by tandem-MS in positive mode using a Qtrap API 6500 from
AB sciex (Ontario, Canada) using rivaroxaban-d4 as internal
standard (20 ng/ml).
ABCB1 Genotyping
Genomic DNA was extracted from whole blood (200 µl)
using the QIAamp DNA blood mini kit (QIAGEN,
Hombrechtikon, Switzerland). ABCB1 c.3435C>T and
c.2677G>T polymorphisms were determined in a single
multiplex PCR, with fluorescent probe melting temperature
analysis on a LightCycler (Roche, Rotkreuz, Switzerland) as
previously described (Ansermot et al., 2008).
CYP3A4/5 Phenotyping
Midazolam was used as a probe to measure the joint activity
of CYP3A4/5 as previously described (Bosilkovska et al., 2014).
Phenotyping was performed 8 days after hospital admission
with concomitant treatment of insulin, enoxaparin 60 mg
b.i.d., atorvastatin 40 mg q.d. (replacing simvastatin from
the day of hospital admission), esomeprazole 40 mg q.d.,
levothyroxine 75 µg q.d., lisinopril 10 mg q.d., extended-release
metoprolol 50 mg q.d., picosulfate 5 mg q.d., and spironolactone
25 mg q.d.
RESULTS
Results from anti-Xa activity and rivaroxaban plasma
concentrations are presented in Table 1. The patient was a
homozygous carrier of both tested ABCB1 variant alleles.
His genotype was TT for the c.2677G>T single nucleotide
polymorphism (SNP) and TT for the c.3435C>T SNP.
CYP3A4/5 phenotyping showed moderately decreased enzymatic
activity, with OH-midazolam/midazolam metabolic ratio
of 0.31.
TABLE 1 | Anti-Xa activity and rivaroxaban plasma concentrations.
Time after the last
rivaroxaban dose
Anti-Xa activity
(ng/ml)
Rivaroxaban plasma
concentrations (ng/ml)
24 h 231 not performed
48 h 110 88.3
60 h 81 not performed
72 h 66 70.5
84 h 66 not performed
96 h 34 35.6
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DISCUSSION
We described the case of a rivaroxaban-treated patient who
presented a non-ST segment elevation myocardial infarction in
the context of a severe anemia probably due to a gastrointestinal
bleeding, 3 months after switching anticoagulant treatment
from acenocoumarol to rivaroxaban. Laboratory investigations
showed high levels of anti-Xa activity and rivaroxaban plasma
concentrations at trough level (24 h after the last dosing)
and an unexpected delay for rivaroxaban clearance, suggesting
impaired rivaroxaban elimination. Our hypothesis is that both
genetic and environmental factors might have contributed
to an increased susceptibility to rivaroxaban in this patient,
e.g., the homozygous presence of ABCB1 variant alleles and
reduced CYP3A4/5 activity due to DDI with simvastatin.
Given that more than one third of the dose is eliminated
as unchanged active drug in the urine (Mueck et al.,
2014), acute renal failure was probably also a contributing
factor. However, renal impairment at admission was moderate
(39 ml/min), not requiring dose adjustment according to the
summary of product characteristics. In a physiologically based
pharmacokinetic (PBPK) model simulating the combined effect
of renal impairment and concomitant erythromycin (combined
P-gp and moderate CYP3A4/5 inhibitor) administration on
rivaroxaban pharmacokinetics, concurrent renal impairment
plus erythromycin resulted in a 2.5–3 fold increase in rivaroxaban
exposure in elderly (Grillo et al., 2012). However, in vivo
data showed that the impact of concomitant renal impairment
and erythromycin administration was less than expected by
the PBPK model. Indeed, a clinical study showed that in
subjects with moderate renal impairment receiving concomitant
erythromycin, rivaroxaban AUC, and Cmax values increased
by approximately 99 and 64%, as compared with subjects with
normal renal function receiving rivaroxaban 10 mg alone (Moore
et al., 2014).
Rivaroxaban belongs to the recently developed class of
direct oral anticoagulants (DOACs). Older OACs such as
vitamin K antagonists (VKAs) are characterized by extensive
hepatic metabolism by CYP450, narrow therapeutic window
and the need for routine coagulation monitoring for dose
adjustment. Their extensive hepatic metabolism implies
multiple potential DDI and an impact of CYP2C9 genetic
polymorphism on their pharmacokinetics (Scaglione, 2013).
DOACs are given at fixed doses without the need for routine
monitoring (Mueck et al., 2014). However, these compounds
are also subject to DDI due to CYP450-mediated metabolism
and/or P-gp and/or BCRP-mediated transport (Scaglione,
2013). About one third of a rivaroxaban dose is renally
excreted as an unchanged form (Mueck et al., 2014) via
glomerular filtration and tubular secretion (Scaglione, 2013).
P-gp and BCRP have been shown to be the major transporters
involved in the active renal secretion of rivaroxaban (Mueck
et al., 2014). The remaining part of the dose is eliminated
after hepatic metabolism. CYP3A4/5 and CYP2J2 are the
isoenzymes involved in rivaroxaban metabolism, while CYP-
independent mechanisms are also contributing (Mueck et al.,
2014).
To the best of our knowledge, no human data have yet
described the impact of CYP3A4/5 and/or ABCB1 (MDR1) and
ABCG2 gene polymorphism on the pharmacokinetics and safety
of rivaroxaban. More than 100 single nucleotide polymorphisms
(SNPs) of the ABCB1 gene region occurring at a >5%
frequency have been described. For the most common coding
SNPs (c.2677G>T, c.3435C>T), allele frequencies exhibits large
interethnic differences, ranging between 2 and 90% across
populations and depending on the SNP (Hodges et al., 2011).
These SNPs are in high linkage disequilibrium and are therefore
observed most frequently as haplotypes. In the Caucasian
population, the TT TT haplotype frequency ranges from 15 to
25% (Marzolini et al., 2004).
An animal study showed that Mdr1a/Mdr1b/Bcrp triple
knockout mice exhibited higher rivaroxaban plasma levels than
wild type mice, with a 1.7 fold increase in plasma concentration
4 h after administration (Gong et al., 2013). The observed effect
was explained by decreased excretion of rivaroxaban via P-gp
and/or BCRP rather than increased absorption as rivaroxaban
oral bioavailability is high (80–100%; Mueck et al., 2014).
ABCB1 genotype of our patient was a homozygous carrier for
both tested SNP (c.2677G>T: TT; and c.3435C>T: TT). This
genotype might have contributed to the high levels of anti-
Xa activity and rivaroxaban plasma concentrations measured.
Indeed, levels of anti-Xa activity as determined by a chromogenic
assay were higher than expected. The trough level of anti-Xa
activity measured 24 h after last drug administration (231 ng/ml)
was in the range of expected Cmax levels (Groupe de travail
RivaMoS Suisse, 2013). The level measured 4 days after last drug
administration (34 ng/ml) was in the range of expected trough
levels (Groupe de travail RivaMoS Suisse, 2013). Rivaroxaban
plasma concentration measured by LC/MS-MS 48 h after
administration (88 ng/ml) was comparable to approximately
8–16 h post-dose predicted levels based on a population
pharmacokinetic model (20 mg q.d. administration) (Mueck
et al., 2011). The plasma concentration measured 4 days after
last drug administration (36 ng/ml) was comparable to expected
trough concentrations. The estimated half-life was increased by
threefold in our patient, approximately 24–30 h as compared
to 11–13 h in the literature for old patients (Mueck et al.,
2014).
Drug-Drug Interaction probably also played a role in
rivaroxaban high levels. Crossover studies in healthy volunteers
have shown significant increases in rivaroxaban systemic
exposure during concomitant administration with strong
inhibitors of CYP3A4/5 (and possibly CYP2J2), P-gp and
BCRP. Steady state administration of ketoconazole led to a
dose-dependent increase in rivaroxaban AUC and Cmax. AUC
and Cmax increased by, respectively, 82% (90% CI 59%, 108%)
and 53% (90% CI 27%, 85%) with ketoconazole 200 mg q.d.
compared with rivaroxaban alone. With a higher dose of 400 mg
q.d., the measured increases in AUC and Cmax were 158% (90%
CI 136%, 182%) and 72% (90% CI 61%, 83%) (Mueck et al.,
2013). As a consequence, the concomitant use of rivaroxaban
with strong CYP3A4/5 and P-gp/BCRP inhibitors should be
avoided due to a potential increase in the risk of bleeding (Mueck
et al., 2013). According to the data from the ROCKET AF study
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(Prevention of Stroke and Embolism Trial in Atrial Fibrillation),
the presence of combined CYP3A4/5 and P-gp inhibitors did not
have any impact on safety outcomes such as bleeding events when
comparing the rivaroxabanand warfarin groups (Piccini et al.,
2016). However, key exclusion criteria included use of a strong
CYP3A4/5 inhibitors or inducers. As recently underscored by
Bouatou et al. (2016) this represents a major bias when analyzing
the impact of polypharmacy pharmacokinetic interactions on the
efficacy and safety of rivaroxaban. Moreover, the prescription of
P-gp affecting drugs in heart failure patients is as frequent as
40–50% as shown by Jungbauer et al. (2010).
In the present case, our patient was receiving long-term
treatment with simvastatin. Recently, an in vitro study has shown
that simvastatin inhibited CYP3A4/5 and P-gp activity (Lee et al.,
2015). An in vivo animal study performed by the same authors
showed that concomitant administration of simvastatin with
nifedipine, a CYP3A/5 and P-gp substrate, significantly increased
the absolute bioavailability of nifedipine by 150% (Lee et al.,
2015). On the other hand, atorvastatin inhibited CYP3A/5 but
not P-gp activity in vitro, and had no impact on nifedipine
pharmacokinetics in vivo (Lee et al., 2015). According to the
FDA classification1, simvastatin would therefore be considered
as a weak CYP3A/5 inhibitor (≥1.25 but <2-fold increase in
AUC). CYP3A4/5 phenotyping, which was performed 8 days after
the patient had been switched from simvastatin to atorvastatin,
showed moderately decreased enzymatic activity as compared to
our study population of healthy volunteers (Bosilkovska et al.,
2014), which could be attributed at least in part to inhibition by
atorvastatin. Although the enzymatic activity was only modestly
decreased with a OH-midazolam/midazolam metabolic ratio of
0.31, compared to 0.50 in healthy volunteers without enzyme
inhibitor/inducer, and 0.22 in the presence of a CYP inhibitor
(voriconazole) (Bosilkovska et al., 2014), the measured phenotype
allowed to rule out an ultrarapid metabolism.
The present case has some limitations. We did not investigate
ABCG2 and CYP2J2 gene polymorphism. Indeed, CYP2J2 is
also subject to genetic variations and the promoter region SNP
(CYP2J2-76G>T; ∗7 allele) reportedly decreases epoxygenase
activity in vivo (Murray, 2016). Moreover, we did not evaluate
P-gp activity in vivo through phenotyping and the DDI with
simvastatin has not been thoroughly investigated. Finally, the
moderate acute renal failure at admission was probably a
contributing factor to rivaroxaban high levels.
1 http://www.fda.gov/Drugs/DevelopmentApprovalProcess/Development
Resources/DrugInteractionsLabeling/ucm080499.htm
CONCLUDING REMARKS
Our patient presented severe normocytic hypochromic anemia
probably due to gastrointestinal bleeding, 3 months after
switching his anticoagulant treatment from acenocoumarol to
rivaroxaban.
Laboratory investigations showed high levels of anti-
Xa activity and rivaroxaban plasma concentrations after
rivaroxaban withdrawal, suggesting reduced rivaroxaban
elimination (estimated half-life: 24–30 h). We suggest that the
homozygous presence of ABCB1 variant alleles and possibly
altered CYP3A4/5 activity due to DDI with simvastatin were
possible contributing factors, in addition to the moderate
decreased renal function.
More clinical data are required to elucidate the impact of
genetic polymorphism on rivaroxaban pharmacokinetics and
bleeding complications. The impact of ABCB1, ABCG2, and
CYP2J2 gene polymorphism on rivaroxaban pharmacokinetics
should be investigated in a phase 1 clinical study in healthy
volunteers. The impact of genetic polymorphism on the
susceptibility to DDI should also be further investigated. Indeed,
the presence of a variant allele could predispose to DDI, as
suggested between warfarin and simvastatin (Andersson et al.,
2012).
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